Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMEC/VI vs Indacaterol + Tiotropium in COPD
NCT02257385Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of umeclidinium, vilanterol in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Oct 2014; status: completed.
02
Drugs
umeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02257385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02257385.